Prof. Thomas J. Macvittie is a professor of radiation oncology and pathology at the University of Maryland School of Medicine and a member of the Molecular and Structural Biology Program at the University of Maryland Marlene and Stewart Greenebaum Cancer Center in Baltimore, is recognized internationally as an expert on the effects of radiation on the hematopoietic and gastrointestinal systems in large animal models and their treatment, in vivo, with supportive care and selected organ-specific drugs. He earned M.S. and Ph.D. degrees in radiation biology at the State University of New York (SUNY) at Buffalo and has more than 30 years of experience as a radiobiologist in the field of experimental hematology. He has published 141 peer-reviewed manuscripts and 43 chapters in books or proceedings.
Dr. MacVittie has served as an advisor to the WHO Collaborating Centers in Radiation Emergency Medical Preparedness and Assistance and the International Council on Radiation Protection and as a member of NATO Radiation Research Study Groups. He is a member of the CDC Strategic National Stockpile Radiation Working Group, the International Association of Radiopathology, the American Society of Hematology, the International Society of Experimental Hematology, Radiation Research and the International Society of Cellular Therapy.
Dr. MacVittie is a member of the editorial board of the journal Stem Cells and serves as an ad hoc reviewer for numerous journals and National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIAID) and Department of Defense grants and contracts. He is also a consultant for the International Atomic Energy Agency (IAEA) and Canadian Defense Research Establishment. Dr. MacVittie was recently invited by the Secretary, U.S. Department of Health and Human Services, to serve on the first National Biodefense Science Board Federal Advisory Committee. Dr. MacVittie is the principal investigator of the sole research contract ($47million/five years) awarded by NIAID to assess the efficacy and mechanism of action for Medical Countermeasures Against Radiological Threats (MCART). The MCART consortium has 15 research and administrative components in the United States, Canada and England.